Role of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis

Volumn , Issue , 2003, Pages 507-561

  Gharaee Kermani, Mehrnaz ^a   Phan, Sem H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65649112689     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (346)

1. Weibel ER, Gehr P, Haies D, Gill J, Bachofen, M. The cell population of the normal lung. In: Bouhuys A. eds., Lung Cells in Disease. Amsterdam: Elsevier/North Holland Biomedical Press, 1976:3–16.
2. Roy SG, Nozaki Y, Phan SH. Regulation of α-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts. Int J Biochem Cell Biol 2001; 33:723–734.
3. Skalli O, Schürch W, Seemayer T, Lagacé R, Montandon D, Pittett B, Gabbiani G. Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest 1989; 60:275–285.
4. Phipps RP. Pulmonary Fibroblast Heterogeneity. In: Phipps RP Ed. Boca Raton: CRC Press, 1992.
5. Schmitt-Gräff A, Desmoulière A, Gabbiani G. Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch 1994; 425:3–24.
6. Phan SH. Role of the myofibroblast in pulmonary fibrosis. Kidney International 1996; 49(54): S-46–S-48.
7. Massaro D. Lung Cell Biology. Vol. 41. New York: Marcel Dekker, 1989.
8. Conrad GW, Hart GW, Chen Y. Differences in vitro between fibroblast-like cells from cornea, heart, and skin of embryonic chicks. J Cell Sci 1977; 26:119–137.
9. Korn JH, Brinckerhoff CE, Edwards RL. Synthesis of PGE2, collagenase and tissue factor by fibroblast substrains: substrains are differently activated for different metabolic products. Collagen 1985; 5:437–447.
10. Karmiol, S, Phan, SH. Fibroblasts and Cytokines. In: Kunkel SL, Remick DG, Eds. Cytokines in Health and Disease. New York: Marcel Dekker, 1992, pp 271–296.
11. Gharaee-Kermani M., and Phan SH. The role of eosinophils in pulmonary fibrosis. Int J Med 1998; 1:43–53.
12. Crystal RG, Ferrans VJ, Basset F. Biological basis of pulmonary fibrosis: In: Crystal RG, West JB, Barnes PJ, Cherniack NS, Weibel ER, eds. The Lung: Scientific Foundations. New York: Raven Press, 1991, pp 2031–2046.
13. Ishizaka MH, Takayama T, Takeuchi T, Umezawa, H. Activity and toxicity of bleomycin. J Antibiot Ser A 1967; 20:15–24.
14. Delena M, Guzzon A, Monfardini S, Bonnadonna G. Clinical, radiological and histopathological studies on pulmonary toxicity induced by treatment with bleomycin. Cancer Chemother Rep 1972; 56:343–356.
15. Phan SH, Varani J, Smith D. Rat lung fibroblast collagen metabolism in bleomycin-induced pulmonary fibrosis. J Clin Invest 1985; 76:241–247.
16. Phan SH, Gharaee-Kermani M., Wolber F, Ryan US. Stimulation of rat endothelial cell transforming growth factor-β production by bleomycin. J. Clin. Invest. 1991; 87:148–154.
17. Zhang K, Gharaee-Kermani M, Jones ML, Warren JS, Phan SH. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol. 1994; 153:4733–4741.
18. Zhang K, Gharaee-Kermani M, McGarry B, Phan SH. In situ hybridization analysis of rat lung a1 (1) and a2 (1) collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection. Lab Invest 1994; 70: 192–202.
19. Zhang H-Y, Gharaee-Kermani M., Zhang K., Karmiol S., Phan, SH. Lung fibroblast α-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis. Am J Pathol 1996; 148:352–361.
20. Clark JG, Starcher BC, Uitto J. Bleomycin-induced synthesis of type I procollagen by human lung and skin fibroblasts in culture. Biochim Biophys Acta 1980; 631:359–370.
21. Sterling KM Jr., Harris MJ, Mitchell JJ, Cutroneo KR. Bleomycin treatment of chick fibroblasts causes an increase of polysomal type I procollagen mRNAs. J Biol Chem 1983; 258:14438–14444.
22. Madri JA, Furthmayr H. Collagen polymorphism in the lung: an immunohistochemical study of pulmonary fibrosis. Hum Pathol 1980; 11:353–366.
23. Raghu G, Striker LJ, Hudson LD, Striker GE. Extracellular matrix in normal and fibrotic human lungs. Am Rev Respir Dis 1985; 131:281–289.
24. Bateman E, Turner-Warwick M, Adelmann-Grill BC. Immunohistochemical study of collagen types in human fetal lung and fibrotic lung disease. Thorax 1981; 36:645–653.
25. Specks U, Nerlich A, Colby TV, Wiest I, Timpul R. Increased expression of type VI collagen in lung fibrosis. Am J Respir Crit Care Med 1995; 6:1956–1964.
26. Selman M, Monotano M, Ramos C, Chapela R. Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis. Thorax 1986; 41: 355–359.
27. Phan SH, Thrall, RS. The role of soluble factors in bleomycin-induced pulmonary fibrosis. Am J Pathol 1981; 106:156–165.
28. Fulmer JD, Bienkowski RS, Cowan MJ, Breul SD, Bradley KM, Ferrans VJ, Robberts WC, and Crystal RG. Collagen concentration and rates of synthesis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1980; 122:289–301.
29. Selman M, Ruiz V, Cabrera S, Segura L, Ramírez R, Barrios R, Pardo A. TIMP- 1, -2, -3, and-4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000; 279:L562–L-574.
30. Absher M, Hildenbran J, Trombley L, Woodcock-Mitchell J, Marsch J. Characteristics of cultured lung fibroblasts from bleomycin-treated rats. Am Rev Respir Dis 1984; 129:125–129.
31. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinase expression. Am J Respir Cell Mol Biol 2001; 24:591–598.
32. Gharaee-Kermani M, Phan SH. Roles of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Design 2001; 7:1083–1103.
33. Zhang K, Flanders KC, Phan SH. Cellular localization of transforming growth factor-b expression in bleomycin-induced pulmonary fibrosis. Am J Pathol 1995; 147:352–361.
34. Gharaee-Kermani M., Phan, SH. Lung Interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1997; 16:438–447.
35. Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH. TNF-α mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J. Immunol 1997; 158:954–959.
36. Gharaee-Kermani M, McGarry B, Lukacs N, Huffnagle G, Egan RW, Phan SH. The role of IL-5 in bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1998; 64:657–666.
37. Zhang K, Rekhter MD, Gordon D, Phan SH. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis: a combined immunohistochemical and in situ hybridization study. Am. J. Pathol 1994; 145:114–125.
38. Gharaee-Kermani M, Nozaki Y, Hatano K, Phan SH. Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. Cytokine 2001; 15:138–147.
39. Coker RK, Laurent GJ. Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998; 11:1218–1221.
40. Massague J, Cheifetz S, Liaho M, Ralph DA, Weis FM, Zentella A. Transforming growth factor-beta. Cancer Surv. 1992; 12:81–103.
41. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993; 8:1–9.
42. Barton DE, Foellmer BE, Du J, Tamm J, Derynck R, Franke U. Chromosomal mapping of genes for transforming growth factor beta 2 and beta 3 in man and mouse: dispersion of TGF-beta gene family. Oncogene Res 1988; 3:323–331.
43. Wojtowicz-pragea SJ. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997; 20:165–177.
44. Sporn MB, Roberts AB. Transforming growth factor-beta: recent progress and new challenges. J Cell Biol 1992; 119:1017–1021.
45. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med 1987; 165:251–256.
46. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84:5788–5792.
47. Kelley J, Shull S, Walsh JJ, Cutroneo KR, Absher M. Auto-induction of transforming growth factor-β in human lung fibroblasts. Am J Respir Cell Mol Biol 1993; 8:417–424.
48. Khalil N, Greenber, AH. The role of TGF-β in pulmonary fibrosis. In: Bock GR, Marsh J, eds. Clinical Applications of TGF-β. Ciba Found Symp 1991; 157:194–211.
49. Nakatsukasa H, Nagy P, Everts RP, Hisa CC, Marsden EC. Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. Clin Invest 1990; 85:1833–1843.
50. Eickelberg O, Kohler E, Reichenberger F, Bertschin S, Woodtli T, Erne P, Perruchoud AP, Roth M. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am J Physiol 1999; 276:L814–824.
51. Zhang H-Y, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor β1. Am J Respir Cell Mol Biol 1999; 21:658–665.
52. Zhang H-Y, Gharaee-Kermani M, Phan SH. Regulation of lung fibroblast α-smooth muscle actin expression, contractile phenotype, and apoptosis by IL-1β. J Immunol 1997; 158:1392–1399.
53. Low RB, Woodcock-Mitchell J, Evans JN, Adler KB. Actin content of normal and of bleomycin-fibrotic rat lung. Am Rev Respir Dis 1984; 129:311–316.
54. Phan SH, Zhang K, Zhang H-Y, Gharaee-Kermani M. The myofibroblast as an inflammatory cell in pulmonary fibrosis. In: Desmoulière A, Tuchweber B, eds. Current Topics in Pathology. Berlin: Springer-Verlag, 1999: pp 173–182.
55. Evans JN, Kelley J, Low RB, Adler KB. Increased contractility of isolated lung parenchyma in an animal model of pulmonary fibrosis induced by bleomycin. Am Rev Respir Dis 1982; 125:89–94.
56. Adler KB, Low RB, Leslie KO, Mitchell J, Evans JN. Biology of disease. Contractile cells in normal and fibrotic lung. Lab Invest 1989; 60:473–485.
57. Breen E, Falco V, Absher M, Cutroneo KR. Subpopulations of rat lung fibroblasts with different amounts of type I and type III collagen mRNAs. J Biol Chem 1990; 265:6286–6290.
58. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factorb1 induces a-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122:103–111.
59. Evans JN, Kelly J, Low RB, Adler KB. Increased contractility of isolated lung parenchyma in an animal model of pulmonary fibrosis induced by bleomycin. Am Rev Rep Dis 1982; 125:89–94.
60. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992; 18:29–43.
61. Barnard JA, Russette ML, Moses HL. The biology of transforming growth factor b. Biochim Biophys Acta 1990; 1032:79–87.
62. Kelley J. Transforming growth factor-β. In: Kelley J, ed. Cytokines of the Lung. New York: Marcel Dekker, 1992: pp 101–137.
63. Gharaee-Kermani M., Denholm EM, Phan SH. Co-stimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271:17779–17784.
64. Breen E, Shull S, Burne S, Absher M, Kelley J, Phan S, Cutroneo KR. Bleomycin regulation of transforming growth factor-β mRNA in rat lung fibroblasts. Am J Respir Cell Mol Biol 1992; 6:146–152.
65. Liu J-Y, Sime PJ, Wu T, Warshamana GS, Pociask D, Tsai S-Y, Brody AR. Transforming growth factor-beta (1) overexpression in tumor necrosis factoralpha receptor knockout mice induces fibroproliferative lung disease. Am J Respir Cell Mol Biol 2001; 25:3–7.
66. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991; 88:6642–6646.
67. Smith EA, Leroy EC. A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol 1990; 95:125S–127S.
68. Peltonen J, Hsiao LL, Jaakola S, Solberg S, Aumailley M, Timpel R, Chu ML, Uitto J. Activation of collagen gene expression in keloids: co-localization of types I and VI collagen and transforming growth factor-beta 1 mRNA. Invest Dermatol 1991; 97:240–248.
69. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, Maki S. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993; 68:154–163.
70. Waltenberger J, Lundin L, Oberg K, Wilander E, Miyazono K, Heldin CH, Funa K. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 1993; 142:71–78.
71. Hoyt DG, Lazo JS. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther 1988; 246:765–771.
72. Raghow R, Irish P, Kang AH. Coordinate regulation of transforming growth factor beta gene expression and cell proliferation in hamster lungs undergoing bleomycin-induced pulmonary fibrosis. J Clin Invest 1989; 84:1836–1842.
73. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, Lindner V. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999; 84:1212–1222.
74. Eickelberg O, Pansky A, Koehler E, Bihl M, Tamm M, Hildebrand P, Perruchoud AP, Kashgarian M, Roth M. Molecular mechanisms of TGF-β antagonism by interferon g and cyclosporine A in lung fibroblasts. FASEB J 2001; 15:797–806.
75. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ, Hart SL, Foster ML, McAnulty RJ. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-β in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001; 158:1411–1422.
76. Ohga E, Matsuse T, Teramoto S, Ouchi Y. Activin receptors are expressed on human lung fibroblast and activin A facilitates fibroblast-mediated collagen gel contraction. Life Sci 2000; 66:1603–1613.
77. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666–3670.
78. Old LJ. Tumor necrosis factor (TNF). Science 1985; 230:630–632.
79. Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990; 269:93–95.
80. Schirren CG, Scharfetter K, Hein R, Braun-Falco O, Kreig T. Tumor necrosis factor alpha induces invasiveness of human skin fibroblasts in vitro. J Invest Dermatol 1990; 94:706–710.
81. Phan SH, Gharaee-Kermani M, McGarry B, Kunkel SL, Wolber FW. Regulation of rat pulmonary artery endothelial cell transforming growth factor-b production by IL-1β and tumor necrosis factor-α. J Immunol 1992; 103–106
82. Warshamana GS, Corti M, Brody AR. TNF-alpha, PDGF, and TGF-beta (1) expression by primary mouse bronchiolar–alveolar epithelial and mesenchymal cells: TNF-alpha induces TGF-beta (1). Exp Mol Pathol 2001; 71:13–33.
83. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7:515–518.
84. Kohno M, Nishizawa N, Tsujimoto M, Nomoto H. Mitogenic signaling pathway of tumor necrosis factor involves the rapid tyrosine phosphorylation of 41,000 and 43,000-M, cytosol proteins. Biochem J 1990; 267:91–98.
85. Schroder JM, Stichering M, Henneicke HH, Preissner WC, Christophers E. IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8–related neutrophil chemotactic proteins in human dermal fibroblasts. J Immunol 1990; 144:2223–2232.
86. Yomamoto T, Katayama I, Nishioka K. Nitrite production in mouse 3T3 fibroblasts by bleomycin-stimulated peripheral blood mononuclear cell factors. Clin Exp Rheumatol 1999; 17:343–346.
87. Karmiol S, Remick DG, Kunkel SL, Phan SL. Regulation of rat pulmonary endothelial cell interleukin-6 production by bleomycin: effects of cellular fatty acid composition. Am J Respir Cell Mol Biol 1993; 9:628–636.
88. Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL. TNF-α mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 1995; 154:5411–5417.
89. Liu JY, Brody AR. Increased TGF-beta1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF-alpha receptor knockout mice. J Environ Pathol Toxicol Oncol 2001; 20:97–108.
90. Liu JY, Brass DM, Hoyle GW, Brody AR. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998; 53:1839–1847.
91. Huaux F, Arras M, Vink A, Renauld JC, Lison D. Soluble tumor necrosis factor (TNF) receptors p55 and p75 and interleukin-10 downregulate TNF-alpha activity during the lung response to silica particles in NMR1 mice. Am J Respir Cell Mol Biol 1999; 21:137–145.
92. Liu JY, Sime PJ, Wu T, Warshamana GS, Pociask D, Tsai SY, Brody AR. Transforming growth factor-beta(1) overexpression in tumor necrosis factoralpha receptor knockout mice induces fibroproliferative lung disease. Am J Respir Cell Mol Biol 2001; 25:3–7.
93. Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, Mason RJ. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 280:L39–L49.
94. Freeburn RW, Kendall H, Dobson L, Egan J, Simler NJ, Millar AB. The 30 untranslated region of tumor necrosis factor-alpha is highly conserved in idiopathic pulmonary fibrosis (IPF). Eur Cytokine Net 2001; 12:33–38.
95. Warshamana GS, Corti M, Brody AR. TNF-alpha, PDGF, and TGF-beta(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: TNF-alpha induces TGF-beta(1). Exp Mol Pathol 2001; 71:13–33.
96. Heledin C-H, Westermark, B. Signal transduction by the receptors for plateletderived growth factor. J Cell Sci 1990; 96:193–196.
97. Nister M, Hammacher A, Mellstrom K, et al. A glioma-derived PDGF A chain homodimer has different functional activities from a PDGF AB heterodimer purified from human platelets. Cell 1988; 52:791–799.
98. Kazlauskas A, Bowen-Pope D, Siefert R, Hart CE, Cooper JE. Different effects of homo- and heterodimers of platelet-derived growth factor A and B chains on human and mouse fibroblasts. EMBO J 1988; 12:3727–3735.
99. Seifert RA, Hart CE, Phillips PE, Forstrom JW, Ross R, Murray MJ, Bowen-Pope DF. Two different subunits associate to create isoformspecific platelet-derived growth factor receptors. J Biol Chem 1989; 264:8771–8778.
100. Orr-Urtreger A, Bedford MT, Do MS, Eisenbach L, Lonai P. Developmental expression of the a receptor for platelet derived growth factor, which is deleted in the embryonic lethal patch mutation. Development 1992; 115: 289–303.
101. Bostrom H, Willetts K, Pekny M, Leveen P, Lindahl P, Hedstrand H, Pekna M, Hellstrom M, Gebre-Medhin S, Schalling M, Nilsson M, Kurland S, Tornell J, Keath JK, Betsholtz C. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 1996; 85:863–873.
102. Coin PG, Lindroos PM, Osornio-Vargas AR, Roggli VL, Bonner JC. Lipopolysaccharide up-regulates platelet-derived growth factor (PDGF) α-receptor expression in rat lung myofibroblasts and enhances responses to all PDGF isoforms. J Immunol 1996; 156:4797–4806.
103. Driscoll KE, Maurer JK, Poynter J, Higgins J, Asquith T, Miller NS. Stimulation of rat alveolar macrophage fibronectin release in a cadmium chloride model of lung injury and fibrosis. Toxicol Appl Pharmacol 1992; 116:30–37.
104. Lindroos PM, Wang YZ, Rice AB, Bonner JC. Regulation of PDGFR-alpha in rat pulmonary myofibroblasts by staurosporine. Am J Physiol Lung Cell Mol Physiol 2001; 280:L354–L362.
105. Seppa H. Grotendorst G, Seppa S, Schiffman E, Martin GR. Platelet-derived growth factor in chemotactic for fibroblasts. J Cell Biol 1982; 92:584–588.
106. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B. Some recent advances in the chemistry and biology of transforming growth factor-beta1. J Cell Biol 1987; 105:1039–1045.
107. Gospodarowicz D. Fibroblast growth factor. Chemical structure and biologic function. Clin Orthop 1990; 257:231–248.
108. Sjolund M, Hedin U, Sejersen T, Heldin C, Thyberg, J. Arterial smooth muscle cells express platelet-derived growth factor (PDGF) a chain mRNA, secrete a PDGF-like mitogen, and bind exogenous PDGF in a phenotype- and growth state-dependent manner. J Cell Biol 1988; 106:403–413.
109. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986; 83:7297–7301.
110. Deuel TF, Senior RM, Huang JS, Griffin GL. Chemotaxis of monocytes and neutrophils to platelet-derived growth factor. J Clin Invest 1982; 69:1046–1049.
111. Tzeng DY, Deuel TF, Huang JS, Bachner RL. Platelet-derived growth factor promotes human peripheral monocyte activation. Blood 1985; 66:179–183.
112. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999; 276:L311–318.
113. Sasaki M, Kashima M, Ito T, Watanabe A, Izumiyama N, Sano M, Kagaya M, Shioya T, Miura M. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin- 1beta and TNF-alpha. Mediators Inflamm 2000; 9:155–160.
114. Sadaki M, Kashima M, Ito T, Watanabe A, Sano M, Kagaya M, Shioya T, Miura M. Effect of heparin and related glycosaminoglycan on PDGF-induced lung fibroblast proliferation, chemotactic response and matrix metalloproteinases activity. Mediators Inflamm 2000; 9:85–91.
115. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type I receptor. Am J Respir Crit Care Med 2000; 161:1999–2004.
116. Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M, Selman M. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86:1055–1064.
117. Hertz MI, Henke CA, Nakhleh RE, Harmon KR, Marinelli WA, Fox JMK, Kubo SH, Shumway SJ, Bolman RM, Bitterman PB. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet derived growth factor. Proc Natl Acad Sci USA 1992; 89:10385–10389.
118. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Malden LT, Masuko H, Sato H. Localization of PDGF-β protein in macrophages in all phases of atherogenesis. Science 1990; 248:1009–1012.
119. Bonner JC, Lindroos PM, Rice AB, Moomaw CR, Morgan DL. Induction of PDGF receptor-α in rat myofibroblasts during pulmonary fibrogenesis in vivo. Am J Physiol 1998; 274:L72–L80.
120. Vignaud JM, Allam M, Martinet N, Pech M, Plenat F, Martinet Y. Presence of platelet-derived growth factor in normal and fibrotic lung is specifically associated with interstitial macrophages, while both interstitial macrophages and alveolar epithelial cells express the c-sis proto-oncogene. Am J Respir Cell Mol Biol 1991; 5:531–538.
121. Martinet Y, Rom WN, Grotendorst GR, Martin GR, Crystal RG. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med 1987; 317: 202–209.
122. Nagaoka I, Trapnell BC, Crystal RG. Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. J Clin Invest 1990; 85:2023–2027.
123. Walsh J, Absher M, Kelly J. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol 1993; 9:637–644.
124. Gurujeyalakshmi G, Hollinger MA, Giri SN. Inhibitory effect of interferon gamma, interleukin-1, interleukin-6 and platelet-derived growth factor-A mRNA expression in bleomycin-mouse model of lung fibrosis. Res Commun Pharmacol Toxicol 1996; 1:1–15.
125. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Lung Cell Mol Physiol 1999; 20:L311–L318.
126. Lasky JA, Friedman M, Zhou Y, Liu J-Y, Poovey H, Brody A. Platelet-derived growth factor receptors are essential in the development of asbestos-induced fibrosis. Chest 2001; 120:61S–62S.
127. Redo M, Baroni T, Bellocchio S, Calvitti M, Lilli C, D’Alessandro A, Muzi G, Lumare A, Abbritti G. Bronchial epithelial cell matrix production in response to silica and basic fibroblast growth factor. Mol Med 2001; 7:83–92.
128. Li H, He B, Que C, Weng B. Expression of TGF-beta 1, PDGF and IGF-1 mRNA in lung of bleomycin-A5-induced pulmonary fibrosis in rats. Chin Med J 1996; 109:533–536.
129. Gospodarowicz D. Fibroblast growth factor. Chemical structure and biological function. Clin Orthop 1990; 257:231–248.
130. Sannes PL, Khosla J, Johnson S, Goralska M, McGahan C, Menard M. Basic fibroblast growth factor in fibrosing alveolitis induced by oxygen stress. Chest 1996; 109:44S-45S.
131. Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992; 7:120–125.
132. Gospodarowicz D. Molecular and developmental biology aspects of fibroblast growth factor. Adv Exp Med Biol 1988; 234:23–39.
133. Buckley-Sturrock A, Woodward SC, Senior RM, Griffin GL, Klagsburn M, Davidson JM. Differential stimulation of collagenase and chemotactic activity in fibroblasts derived from rat wound repair tissue and human skin by growth factors. J Cell Physiol 1989; 138:70–78.
134. Nozaki Y, Liu T, Hatano K, Gharaee-Kermani M, Phan, SH. Induction of telomerase activity in fibroblasts from bleomycin-injured lungs. Am J Respir Cell Mol Biol 2000; 23:460–465.
135. Liu T, Ullenbruch M, Nozaki Y, Phan SH. Regulation of telomerase activity in lung fibroblasts. Am J Respir Cell Mol Biol 2002; 26:534–540.
136. Stiles AD, D’Ercole AJ. The insulin-like growth factors and the lung. Am J Respir Cell Mol Biol 1990; 3:93–100.
137. Stiles AD, Moats-Staats BM. Production and action of insulin-like growth factor I/somatomedin C in primary cultures of fetal lung fibroblasts. Am J Respir Cell Mol Biol 1989; 1:21–26.
138. Elias JA, Zitnik RJ, Ray P. Fibroblast immune-effector function. In: Phipps RP, ed. Pulmonary fibroblast heterogeneity. Boca Raton, FL: CRC Press, 1992: pp 295–322
139. Pledger WJ, Stiles CD, Antoniades HN, et al. Introduction of DNA synthesis in BALB/c 3T3 cells by serum components reevaluation of the commitment process. Proc Natl Acad Sci USA 1977; 74:4481–4485.
140. Stiles CD, Capone GT, Scher CD, et al. Dual control of cell growth by somatomedin and platelet-derived growth factor. Proc Natl Acad Sci USA 1979; 76:1279–1283.
141. Cao B, Guo Z, Zhu Y, Xu W. The potential role of PDGF, IGF-1, TGF-beta expression in idiopathic pulmonary fibrosis. Chin Med J 2000; 113: 776–782.
142. Soo-taek UH, Inoue Y, King TE Jr., Chan ED, Newman LS, Riches DWH. Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1626–1635.
143. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukjwa T, Kira S. Localization of platelet-derived growth and insulin-like growth factor 1 in the fibrotic lung. Am J Respir Crit Care Med 1995; 152:2084–2089.
144. Bloor CA, Knight RA, Kedia RK, Spiteri MA, Allen JT. Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 2001; 164:265–272.
145. Uh S-T, Inoque Y, King TE Jr., Chan ED, Newman LS, Riches DWH. Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1626–1635.
146. Yateman ME, Claffey DC, Cwyan Hughes SC, Frost VJ, Wass JAH, Holly JMP. Cytokines modulate the sensitivity of human fibroblasts to stimulate with insulin-like growth factor- (IGF-1) by altering endogenous IGF-binding protein production. J Endocrinol 1993; 137:151–159.
147. Maeda A, Hiyama K, Yamakido H, Ishioka S, Yamakido M. Increased expression of platelet-derived growth factor-1 in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest 1996; 109:780–786.
148. Goldstein RH, Poliks CF, Pilch pulmonary fibrosis, et al. Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibrosis. Endocrinology 1989; 124:964–970.
149. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsburn M. A heparinbinding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251:936–939.
150. Decker SJ. Epidermal growth factor and transforming growth factor-alpha induce differential processing of the epidermal growth factor receptor. Biochem Biophys Res Commun 1990; 166:615–621.
151. Derynck R. Transforming growth factor-alpha: structure and biological activities. J Cell Biochem 1986; 32:293–304.
152. De Larco JE, Todaro GJ. Growth factors from murine sarcoma virus–transformed cells. Proc Natl Acad Sci USA 1978; 75:4001–4005.
153. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232:1250–1253.
154. Silver MH, Murray JC, Pratt RM. Epidermal growth factor stimulates type-V collagen synthesis in cultured murine palatal shelves. Differentiation 1984; 27:205–208.
155. Turley EA, Hollenberg MD, Pratt RM. Effect of epidermal growth factor/urogastrone on glycosaminoglycan synthesis and accumulation in vitro in the developing mouse palate. Differentiation 1985; 28:279–285.
156. Turksen K, Choi Y, Fuchs E. Transforming growth factor alpha induces collagen degradation and cell migration in differentiating human epidermal raft cultures. Cell Regul 1991; 2:613–625.
157. Hosono T, Ito A, Sato T, Nagase H, Mori Y. Translational augmentation of promatrix metalloproteinase 3 (prostromelysin 1) and a tissue inhibitor of metalloproteinases (TIMP)-1 mRNAs by epidermal growth factor and transforming growth factor a, but not by interleukin-1a or 12-O-tetradecanoylphorbol 13-acetate in human uterine cervical fibroblasts: the possible involvement of an atypical protein kinase C. Biol Pharm Bull 1996; 19:1285–1290.
158. Lyons JG, Birkedal-Hansen B, Pierson MC, Whitelock JM, Birkedal-Hansen H. Interleukin-1β and transforming growth factor-α/epidermal growth factor induce expression of Mr 95,000 type IV collagenase/gelatinase and interstitial fibroblasttype collagenase by rat mucosal keratinocytes. J Biol Chem 1993; 268: 19143–19151.
159. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994; 269:9352–9360.
160. Ruocco S, Lallemand A, Tournier JM, Gaillard D. Expression and localization of epidermal growth factor, transforming growth factor-α, and localization of their common receptor in fetal human lung development. Pediatr Res 1996; 29:448–455.
161. Strandjord TP, Clark JG, Guralnick DE, Madtes DK. Immunolocalization of transforming growth factor-α, epidermal growth factor (EGF), and EGFreceptor in normal and injured developing human lung. Pediatr Res 1995; 38:851–856.
162. Baughman RP, Lower EE, Miller MM, Bejarano PA, Heffelfinger SC. Overexpression of transforming growth factor-α and epidermal growth factorreceptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:57–61.
163. Chesnutt A, Kheradmand F, Folkesson HG, Alberts MA, Matthay MA. Soluble transforming growth factor-α is present in the pulmonary edema fluid of patients with acute lung injury, Chest 1997; 111:652–656.
164. Madtes DK, Busby HK, Strandjord TP, Clark JG. Expression of transforming growth factor-α and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. Am J Respir Cell Mol Biol 1994; 11:540–551.
165. Madtes DK, Elston AL, Hackman RC, Dunn AR, Clark JG. Transforming growth factor-α deficiency reduces pulmonary fibrosis in transgenic mice. Am J Respir Cell Mol Biol 1999; 20:924–934.
166. Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific inhibitors of plateletderived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol. 1999, 155:213–221.
167. Munker R, Gasson J, Ogawa M, Koeffler HP. Recombinant human tumor necrosis factor induced production of granulocyte-monocyte colony stimulating factor. Nature 1986; 323:79–82.
168. Zucali JR, Dinarello CA, Oblin DJ, Gross MA, Anderson L, Weiner RS. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colonystimulating activity and prostaglandin E2. J Clin Invest 1986; 77:1857–1863.
169. Gauldie J, Jordana M, Cox G. Myeloid growth factors in the lung. In: Kelley J, ed. Cytokines of the Lung. New York: Marcel Dekker, 1992: pp 383–402.
170. Janson RW, King TE, Hance KR et al. Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148:495–503.
171. Kawada A, Hiruma M, Noguchi H, Ishibashi A, Motoyoshi K, Kawada I. Granulocyte and macrophage colony-stimulating factors stimulate proliferation of human keratinocytes. Arch Dermatol Res 1997; 289:600.
172. Tanaka M, Dykes P, Marks R. Keratinocyte growth stimulation by granulocytemacrophage colony-stimulating factor (GM-CSF). Keio J Med 1997; 46:184.
173. Reed JH, Rice W, Zsengeller Z, Wert S, Dranoff G, Whitsett J. GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice. Am J Physiol 1997; 273:L715.
174. Piquet PF, Grau GE, de Kossordo S. Role of granulocyte-macrophage colonystimulating factor in pulmonary fibrosis in mice by bleomycin. Exp Lung Res 1997; 19:579–587.
175. Christensen PJ, Bailie MB, Goodman RE, O’brien AD, Toews GB, Paine R., III Role of diminished epithelial GM-CSF in the pathogenesis of bleomycininduced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2000; 279:L487–495.
176. Moore BB, Coffey MJ, Christensen P, Sitterding S, Ngan R, Wilke CA, McDonald R, Phare SM, Peters-Golden M, Paine R, III, Toews GB. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J Immunol 2000; 165:4032–4039.
177. Rubbia-Brandt L, Sappino A-P, Gabbiani G. Locally applied GM-CSF induces the accumulation of a-smooth muscle actin containing myofibroblasts. Virchows Arch B 1991; 60:73–82.
178. Vyalov SL, Gabbiani G, Kapanci Y. Rat alveolar myofibroblasts acquire a-smooth muscle actin expression during bleomycin-induced pulmonary fibrosis. Am J Pathol 1993; 143:1754–1765.
179. Xing Z, Ohkawara Y, Jordana M, Graham FL, Gauldie J. Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions. J Clin Invest 1996; 97:1102–1110.
180. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997; 8:253–265.
181. Tocci MJ, Schmidt JA. Interleukin-1: structure and function. In: Remick DG, Friedland JS, eds. Cytokines in Health and Disease. New York: Marcel Dekker, 1997:1–27.
182. Elias JA, Freundlich B, Kern JA, Rosenbloom J. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 1990; 97: 1439–1445.
183. Larsen CG, Zachariae CO, Oppenheim JJ, Matsushima K, Production of monocyte chemotactic and activating factor (MCAF) by human dermal fibroblasts in response to interleukin 1 or tumor necrosis factor. Biochem Biophys Res Commun 1989; 160:1403–1408.
184. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K. Production of interleukin 8 by human dermal fibroblasts and keratinocytes in response to interleukin 1 or tumor necrosis factor. Immunology 1989; 68:31–36.
185. Zucali JR, Dinarello CA, Oblon DJ, Gross MA, Anderson L, Weiner RS. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest 1986; 77: 1857–1863.
186. Dinarello CA. Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin). Year Immunol 1986; 2:68–89.
187. Dinarello CA. Interleukin-1. In: Thomson A, ed. The Cytokine Handbook. London: Academic Press, 1991, pp 47–82.
188. Tingstrom A, Heldin CH, Rubin K. Regulation of fibroblast-mediated collagen gel contraction by platelet-derived growth factor, interleukin-1 alpha and transforming growth factor-beta 1. J Cell Sci 1992; 102:315–322.
189. Fan JM, Huang XR, Ng YY, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY. Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-beta1-dependent mechanism in vitro. Am J Kidney Dis 2001; 37:821–831.
190. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis J Clin Invest 2001; 107:1529–1536.
191. Monroe JG, Haldar S, Prystowsky MB, Lammie P. (1988) Lymphokine regulation of inflammatory processes: Interleukin-4 stimulates fibroblast proliferation. Clin Immunol Immunopathol 1988; 49:292–298.
192. Mosmann TR, Coffiman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145–168.
193. Cher DJ, Mosmann TR. Two types of murine helper T cell clones 2. Delayedtyped hypersensitivity is mediated by TH1 clones. J Immunol 1987; 138:3688–3694.
194. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: Il-2 and IL-4 are required for in vitro generation of IL-4 producing cells. J Exp Med 1990; 172:921–928.
195. Swain SL, Weinberg AD, English M, Hutson G. IL-4 directs the development of Th2 effectors. J Immunol 1990; 145:3796–3806.
196. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362:245–247.
197. Gross A, Ben Sasson SZ, Paul WE. Anti-IL-4 diminishes in vivo priming for antigen specific IL-4 production by T cells. J. Immunol. 1993; 150:2112–2120.
198. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4) producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4 producing cells. J Exp Med 1990; 172:921–928.
199. Mosmann TR, Coffiman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145–168.
200. Grabstein K, Eisenman J, Mochizuki D, Shanebeck K, Conlon P, Hopp T, March C, Gillis S. Purification to homogeneity of β cell stimulating factor. A molecule that stimulates proliferation of multiple lymphokine-dependent cell lines. J Exp Med 1986; 163:1405–1414.
201. Ohara J, Paul WE. Receptors for β-cell stimulatory factor-1 expressed on cells of hematopoietic lineage. Nature 1987; 325:537–540.
202. Wallace WAH, Ramage EA, Lamb D, Howie SEM. A type 2 (Th2 like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol 1995; 101:436–441.
203. Wallace WAH, Howie SEM. Immunoreactive interleukin 4 and interferon-g expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 1999; 187:475–480.
204. Mosmann TR, Cherwinski H, Bond MW, Geildin MA, Coffman RL. Two types of murine helper T cell clones. 1. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348–2357.
205. Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991; 12:256–257.
206. Gay S, Jones RE Jr., Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92:301–303.
207. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin- 4, interleukin 6, tumor necrosis factor a, and interferon-γ levels in sera from patients with scleroderma. Athritis Rheum 1992; 35:67–72.
208. Postlethwaite AE, Sayer JM. Fibroblast chemotaxis induction by human recombinant interleukin- 4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70–88 and 89–122. J Clin Invest 1991; 87:2147–2152.
209. Patel BKR, Wang L-M, Lee C-C, Taylor WG, Pierce JH, LaRochelle WJ. Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin- 4 signal transudation pathways in NIH 3T3 fibroblasts. J Biol Chem 1996; 271:175–182.
210. Naravanan AS, Page RC. Biosynthesis and regulation of type V collagen in diploid human fibroblasts. J Biol Chem 1983; 258:694–699.
211. Seppa H, Grotendorst G, Seppa S, Schiffmann E, Martin GR. Platelet-derived growth factor in chemotactic for fibroblasts. J Cell Biol 1982; 92:584–588.
212. Lopez AF, Sanderson CJ, Gamble JR, Campbell DH, Yound IG, Vadas MA. Recombinant human interleukin-5 is a selective activator of human eosinophil function. J Exp Med 1988; 167:219–233.
213. Takatsu KA, Tominaga AAA, Hamaoka T. Antigen-induced Y cell–replacing factor (TRF). I. Functional characterization of helper T lymphocytes and genetic analysis of TRF production. J Immunol 1980; 124:2414–2422.
214. Swain SL, Duton RW. Production of a B cell growth promoting activity. (DL) BCGF from a cloned T cell line and its assay on the BCL, B cell tumor. J Exp Med 1982; 156:1821–2834.
215. Sanderson CJ, O’Garra A, Warren DJ, Klaus GB. Eosinophil differentiation factor also has B-cell growth factor activity: proposed name-interleukin-4. Proc Natl Acad Sci USA 1986; 84:437–440.
216. Kung TT, Stelts DM, Zurcher JA, Adams III GK, Egan RW, Kreutner W, Watnick AS, Jones H, Chapman RW. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995; 13:360–365.
217. Clutterbuck EK, Hirst EMA, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures; comparison and interactions with IL-1, IL-3, IL-5 and GMCSF. Blood 1979; 73:1504–1512.
218. Hao H, Cohen DA, Jennings CD, Bryson JS, Kaplan AM. Bleomycin-induced pulmonary fibrosis is independent of eosinophils. J Leukoc Biol 2000; 68:515–521.
219. Hirano T. Interleukin-6. In: Thomson A, ed. The Cytokine Handbook. London: Academic Press, 1991: pp 169–190.
220. Akashi M, Loussararian AH, Adelman DC, Saito M, Koeffler HP. Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation. J Clin Invest 1990; 85:121–129.
221. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265:621–636.
222. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6:315–325.
223. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991; 97:686–692.
224. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990; 8: 253–278.
225. Sotres-Vega A, Olmos-Zuniga R, Jasso-Victoria R, Gaxiola-Gaxiola M, Santillan-Doherty P. Effect of perfusion and preservation on IL-1β, IL-6, and IL-10 production in murine lung. J Invest Surg 2001; 14:331–340.
226. Feghali CA, Bost KL, Boulware DW, Levy LS. Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994; 17:309–318.
227. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, Ciliberto G. Interleukin 6 is required for the development of collageninduced arthritis. J Exp Med 1998; 187:461–468.
228. Kondo K, Okada T, Matsui T, Shinji K, Date K, Yoshihara M, Nagatta Y, Takagi H, Yoneda K, Yoshihara M, Nagata Y, Takagi H, Yoneda M, Sugie I. Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine 2001; 13:220–226.
229. Smith RE, Strieter RM, Phan SH, Lukacs N, Kunkel S. TNF and IL-6 mediate MIP-1α expression in bleomycin-induced lung injury. J Leukoc Biol 1998; 64:528–536.
230. Strieter RM, Kunkel SL, Showell HJ, Remick DG, Phan SH, Ward PA, Marks RM. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β. Science 1989; 243:1467–1471.
231. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243:1464–1466.
232. Baggioloni M, Dewald B, Walz A. Interleukin-8 and related chemotactic cytokines. In: Gallin JI, Goldstein IM, Snyderman R, eds. Basic Principles and Clinical Correlates. New York: Raven Press, 1992, pp 247–264.
233. Kwon OJ, Au BT, Collins PD, Adcock IM, Mak JC, Robbins RR, Chung KF, Barnes PJ. Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells. Am J Physiol 1994; 267: L398–L405.
234. Standiford TJ, Kunkel SL, Basha MA, Chensue SW, Lynch JP, Toews GB, Westwick J, Strieter RM. Interleukin-8 gene expression by a pulmonary epithelial cell line: a model for cytokine networks in the lung. J Clin Invest 1990; 86: 1945–1953.
235. Carre PC, Mortenson RL, King TEJ, Noble PW, Sable CL, Riches DWH. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. J Clin Invest 1991; 88:1802–1810.
236. Ziegenhagen MW, Zabel P, Zissel G, Schlaak M, Müller-Quernheim J. Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med 1998; 157:762–768.
237. Keane MP, Arenberg DA, Lynch JP, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159:1437–1443.
238. Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci USA 1988; 85:6934–6938.
239. Moeller J, Hultner L, Schmitt E, Dormer P. Partial purification of a mast cell growth–enhancing activity and its separation from IL-3 and IL-4. J Immunol 1989; 142:3447–3451.
240. Renauld JC, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J. Human P40/IL-9: expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J Immunol 1990; 144: 4235–4241.
241. Houssiau FA, Renauld JC, Stevens M, Lehmann F, Lethe B, Coulie PG, Van Snick J. Human T cell lines and clones respond to IL-9. J Immunol 1993; 150:2634–2640.
242. Holbrook ST, Ohls RK, Schibler KR, Yang YC, Christensen RD. Effect of interleukin-9 on clonogenic maturation and cell-cycle status of fetal and adult hematopoietic progenitors. Blood 1991; 77:2129–2134.
243. Hoyle GW, Brody AR. Perspective: IL-9 and lung fibrosis: a Th2 good guy? Am J Respir Cell Mol Biol 2001; 24:365–367.
244. Arras M, Huaux F, Vink A, Delos M, Coutelier J-P, Many M-C, Barbarin V, Renauld J-C, Lison D. Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model. Am J Respir Cell Mol Biol 2001; 24:368–375.
245. Moore KW, Rousset F, Banchereau J. Evolving principles in immunopathology: interleukin 10 and its relationship to Epstein-Barr virus protein BCRF1. Springer Semin Immunopathol 1991; 13:157–166.
246. Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM. Interleukin-10 inhibits interleuki-8 production in human neutrophils. Blood 1994; 83: 2678–2683.
247. Florentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell IV: Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081–2095.
248. Defrance T, Vanbervliet B, Biere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti- CD40–activated naïve human B cells to secrete immunoglobulin. A J Exp Med 1992; 175:671–682.
249. Cox G. IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Am J Physiol Lung Cell Mol Physiol 1996; 271:L566–L571.
250. Martinez JA, King TE Jr., Brown K, Jennings CA, Borish L, Mortenson RL, Khan TZ, Bost TW, Riches DW. Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 1997; 273:L676–L683.
251. Aral T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H, Nishino K, Osaki T, Tachibana I, Kaneda Y, Hayashi S. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 2000; 278:L914–L922.
252. Huaux F, Louahed J, Hudspith B, Meredith C, Delos M, Renauld J-C, Lison D. Role of interleukin-10 in the lung response to silica in mice Am J Respir Cell Mol Biol 1998; 18:51–59.
253. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996; 17:214–217.
254. Huaux F, Lardot C, Arras M, Delos M, Many M-C, Coutelier J-P, Buchet J-P, Renauld J-C, Lison D. Lung fibrosis induced by silica particles in NMR1 mice is associated with an upregulation of the p40 subunit of interleukin-12 and Th-2 manifestations. Am J Respir Cell Mol Biol 1999; 20:561–572.
255. Vancheri C, Mastruzzo C, Tomaselli V, Sortino MA, D’Amico L, Bellistrí G, Pistorio MP, Salinaro ET, Palermo F, Mistretta A, Crimi N. Normal human lung fibroblasts differently modulate interleukin-10 and interleukin-12 production by monocytes. Am J Respir Cell Mol Biol 2001; 25:592–599.
256. Keane MP, Belperio JA, Burdick MD, Strieter RM. IL-12 attenuates bleomycininduced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2001; 281: L92–L97.
257. Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Hara N. Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. Am J Physiol Lung Cell Mol Physiol 2001; 280:L1128–L1137.
258. Mckenzie AN, Li X, Largespada DA, Sato A, Kaneda A, Zurawski SM, Doyle EL, Milatovich A, Francke U, Copeland NG, Jenkins NA, Zurawski G. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 1993; 150:5436–5444.
259. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998; 18:60–65.
260. Mckenzie ANJ, Culpepper JA, Malefyt RDW, Biere F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, Menon S, DeVries JE, Banchereau J, Zuawski G. Interleukin 13, a T cell derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993; 90:3735–3739.
261. de Vries JE The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998; 102:165–169.
262. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24:328–332.
263. Chiramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2–dominated inflammatory response. J Clin Invest 1999; 104:777–785.
264. Fallon PG, Richardson EJ, Mckenzie GJ, Mckenzie AN. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000; 164:2585–2591.
265. 1. J Exp Med 2001; 194:809–821.
266. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779–788.
267. Chen ES, Greenlee BM, Willis-Karp M, Moller DR. Attenuation of lung inflammation and fibrosis in interferon-g-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol 2001; 24:545–555.
268. Tamura R, Sato A, Chida K, Suganuma H. Fibroblasts as target and effector cells in Japanese patients with sarcoidosis. Lung 1998; 176:75–87.
269. Narayanan AS, Whithey J, Souza A, Raghu G. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992; 101:1326–1331.
270. Sempowski GD, Derdak S, Phipps RP. Interleukin-4 and interferon-gamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol 1996; 167:290–296.
271. Granstein RD, Flotte TJ, Amento EP. Interferons and Collagen Production. J Invest Dermatol 1990; 95:75S–80S.
272. Okada T, Sugie I, Aisaka K. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res 1993; 12:87–91.
273. Eickelberg O, Pansky A, Koehler E, Bihl M, Tamm M, Hildebrand P, Perruchoud AP, Kashgarian M, Roth M. Molecular mechanisms of TGF- (beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J 2001; 15:797–806.
274. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L-H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341:1264–1269.
275. Walker C, Bauer W, Braun RK, Menz G, Braun P, Schwarz F, Hansel TT, Villiger B. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophils. Am J Respir Crit Care Med 1994; 150:1038–1048.
276. Sharma SK, Maclean JA, Pinto C, Kradin RL. The effect of an anti-CD-3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Am J Respir Crit Care Med 1996; 154:193–200.
277. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med 1996; 1:1174–1178.
278. Taub DD, Oppenheim JJ. Chemokines, inflammation and the immune system. Ther Immunol 1994; 1:229–246.
279. Fahey TJ, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, Shires GT, Cerami A, Sherry B. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 1992; 148:2764–2769.
280. Jiang Y, Beller DI, Frendl G, Graves DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992; 148:2423–2428.
281. Standiford TJ, Kunkel SL, Lukacs NW, Greenberger MJ, Danford JM, Kunkel RG, Strieter RM. Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. J Immunol 1995; 155:1515–1524.
282. Rollins B. JE/MCP-1: an early response gene encodes a monocyte-specific cytokine. Cancer Cells 1991; 3:517–524.
283. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169:1485–1490.
284. Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, Maeda N. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci 1997; 94: 12053–12058.
285. Allavena P, Bianchi G, Zhou D, van Damme J, Jflek P, Sozzani S, Mantovani A. 1994. Induction of natural killer cell migration by monocyte chemotactic protein- 1, -2, and -3. Eur J Immunol 1994; 24:3233–3236.
286. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A. 1998. Rapid and coordinated switch in chemokine receptor expression during dendritic cell mutation. Eur J Immunol 1998; 28:2760–2769.
287. Chensue SW, Warmington KS, Ruth JH, Sanghi PS, Lincoln P, Kunkel SL. Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation. Relationship to local inflammation, Th cell expression, and IL-12 production. J Immunol 1996; 157:4602–4608.
288. Lloyd C, Minto A, Dorf M, Proudfoot A, Wells T, Salant D, Gutierrex-Ramos J. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997; 185:1371.
289. Strieter RM, Wiggins R, Phan SH, Wharram BL, Showell HJ, Remick DG, Chensue SW, Kunkel SL. Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells. Biochem Biophys Res Commun 1989; 162:694–701.
290. Antoniades HN, Neville-Golden J, Galanopoulos T, Kradin RL, Valente AJ, Graves DT. Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci 1992; 89:5371–5375.
291. Moore BB, Paine R, III, Christensen PJ, Moore TA, Sitterding S, Ngan R, Wilke CA, Kuziel WA, Toews GB. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001; 167: 4368–4377.
292. Smith RE, Strieter RM, Phan SH, Lukacs NW, Huffnagle GB, Wilke CA, Burdick MD, Lincoln P, Evanoff H, Kunkel SL Production and function of murine macrophage inflammatory protein-1a in bleomycin-induced lung injury. J Immunol 1994; 153:4704–4712.
293. Smith RE, Strieter RM, Zhang K, Phan SH, Standiford TJ, Lukacs NW, Kunkel SL. A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol 1995; 57:782–787.
294. Tokuda A, Itakura M, Onai N, Kimura H, Kuriyama T, Matsushima K. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol 2000; 164:2745–2751.
295. Charo IF. CCR2: from cloning to the creation of knockout mice. Chem Immunol 1999; 72:30–41.
296. Frade JM, Mellado M, del Real G, Gutierrez-Ramos JC, Lind P, Martinez AC. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor.
297. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394:894–897.
298. Fries KM, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willis RA, Phipps RP. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 1994; 72:283–292.
299. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277:C1–C19.
300. Burns AR, Simon SI, Kukielka GL, Rowen JL, Lu H, Mendoza LH, Brown ES, Entman ML, Smith CW. Chemotactic factors stimulate CD18-dependent canine neutrophil adherence and mortality on lung fibroblasts. J Immunol 1996; 156:3389–3401.
301. Sappino AP, Schurch W, Gaggiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990; 63:144–161.
302. Schmitt-Graff A, Desmouliere A, Gabbiani G. Heterogeneity of myofibroblast phenotypic features: an example of fibroblast cell plasticity, Virchows Arch 1994; 425:3–24.
303. Schmitt-Gräff A, Skalli O, Gabbiani G. α-smooth muscle actin is expressed in a subset of bone marrow stromal cells in normal and pathological conditions. Virchows Arch B 1989; 57:291–302.
304. Darby I, Skalli O, Gabbiani G. α-smooth muscle actin is transiently expressed by myofibroblast during experimental wound healing. Lab Invest 1990; 63:21–29.
305. Feigl W, Susani M, Ulrich W, Matajka M, Losert U, Sinzinger H. Organization of experimental thrombosis by blood cells. Evidence of the transformation of mononuclear cells into myofibroblasts and endothelial cells. Virchows Arch A. 1985; 406:133–148.
306. Skalli O, Schürch W, Seemayer T, et al. Myofibroblast from diverse pathological settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest 1989; 60:275–285.
307. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331:1286–1292.
308. Gabbiani G. The cellular derivation and the life span of the myofibroblast. Pathol Res Pract 1996; 192:708–711.
309. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ. The origin of myofibroblast in breast cancer: recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995; 95:859–873.
310. Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Mu W, Nikolic-Paterson DJ, Atkins RC, Lan HY. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998; 54:864–876.
311. Smith RE. Chemotactic cytokines mediate leukocyte recruitment in fibrotic lung disease. Biol Signals 1996; 5 (4):223–233.
312. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138:1257–1265.
313. Ludwicka A, Trojanowsk M, Smith EA, Baumann M, Strange C, Korn JH, Smith T, Leroy EC, Silver RM. Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma. J Rheumatol 1992; 19:1716–1723.
314. Ronnov-Jessen L, Petersen OW. Induction of a-smooth muscle actin by transforming growth factor-b1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 1993; 68:696–707.
315. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100:768–776.
316. Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, Ben-Efraim S, Spirer Z. Effect of endothelin-1 on a-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 1999; 21:759–775.
317. Hashimoto S, Gon Y, Takeshita I, Maruoka S, Horie T. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2- terminal kinase-dependent pathway. J Allergy Clin Immunol 2001; 107: 1001–1008.
318. Mattey DL, Dawes PT, Nixon NB, Slater H. Transforming growth factor β1 and interleukin 4 induced α-smooth muscle actin expression and myofibroblast-like differentiation in human synovial fibroblasts in vitro: modulation by basic fibroblast growth factor. Ann Rheum Dis 1997; 56:426–431.
319. Mermall V, Post PL, Mooseker MS. Unconventional myosins in cell movement, membrane traffic, and signal transduction. Science 1998; 279:527–533.
320. Desmoulière A, Rubbia-Brandt L, Abdiu A, Walz T. Maciera-Coelho. α-Smooth muscle actin is expressed in a subpopulation of cultured and cloned fibroblasts and is modulated by γ-interferon. Exp Cell Res 1992; 201:64–73.
321. Mitchell JJ, Woodcock-Mitchell J, Low RB, Absher M. Modulation of a-smooth muscle actin by growth state and TGF-β in lung myofibroblasts. J Cell Biol 1991; 15:161a.
322. Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994; 127: 2037–2048.
323. Friedman SL. Closing in on the signals of hepatic fibrosis. Gastroenterology 1997; 112:1406–1409.
324. Lindroos PM, Wang Y-Z, Rice AB, Bonner JC. Regulation of PDGFR-α in rat pulmonary myofibroblasts by staurosporine. Am J Physiol Lung Cell Mol Physiol 2001; 280:L354–L362.
325. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T. Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinasedependent pathway. Am J Respir Crit Care Med 2001; 163:152–157.
326. Hautmann MB, Madsen CS, Owens GK. A transforming growth factor-β (TGF β) control element drives TGF-β induced stimulation of smooth muscle a-actin gene expression in concert with two CArG elements. J Biol Chem 1997; 272:10948–10956.
327. Adam PJ, Regan CP, Hautmann MB, Owens GK. Positive and negative-acting Krüppel-like transcription factors bind a transforming growth factor β control element required for expression of the smooth muscle cell differentiation marker SM22 a in vivo. J Biol Chem 2000; 275:37798–37806.
328. Wang J, Seth A, McCulloch CA. Force regulates smooth muscle actin in cardiac fibroblasts. Am J Physiol 2000; 279:H2776–2785.
329. Scaffidi AK, Moodley YP, Weichselbaum M, Thompson PJ, Knight DA. Regulation of human lung fibroblast phenotype and function by vitronectin and vitronectin integrins. J Cell Sci 2001; 114:3507–3516.
330. Pohl WR, Conlan MG, Thompson AB, Ertl RF, Romberger DJ, Mosher DF, Rennard SI. Vitronectin in bronchoalveolar lavage fluid is increased in patients with interstitial lung disease. Am Rev Respir Dis 1991; 143:1369–1375.
331. Hellerbrand, Wang S. C., Tsukamoto H, Brenner DA, Rippe RA. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology 1996; 24:670–676.
332. Piguet PF, Rosen H, Vesin C, Grau GE. Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies. Am Rev Respir Dis 1993; 147:435–441.
333. Levine D, Rockey DC, Milner TA, Breuss JM, Fallon JT, Schnapp LM. Expression of the integrin a8b1 during pulmonary and hepatic fibrosis. Am J Pathol 2000; 156:1927–1935.
334. Clore JN, Cohen IK, Diegelmann RF. Quantitation of collagen types I and III during wound healing in rat skin. Proc Soc Exp Biol Med 1979; 161:337–340.
335. Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995; 146:56–66.
336. Hansson GK, Hellstrand M, Rymo L, Rubbia L, Gabbiani G. Interferon γ inhibits both proliferation and expression of differentiation-specific α-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989; 170:1595–1608.
337. Yokozeki M, Baba Y, Shimokawa H, Moriyama K, Kuroda T. Interferon-γ inhibits the myofibroblastic phenotype of rat palatal fibroblasts induced by transforming growth factor-β1 in vitro. FEBS Lett 1999; 442:61–64.
338. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136–151.
339. Pache JC, Christakos PG, Gannon DE, Mitchell JJ, Low RB, Leslie KO, Myofibroblasts in diffuse alveolar damage of the lung. Mod Pathol 1998; 11:1064–1070.
340. Fireman E, Shahar I, Greif J, Messer Y, Dabush S, Shoval S. Morphological and biochemical properties of alveolar fibroblasts in interstitial lung diseases. Lung 2001; 179:105–117.
341. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-b signaling in cancer. J Natl Cancer Inst 2000; 92:1388–1402.
342. Petridou S, Maltseva O, Spanakis S, Masur SK. TGF-β receptor expression and smad2 localization are cell density dependent in fibroblasts. Invest Ophthalmol Vis Sci 2000; 41:89–95.
343. Dooley S, Streckert M, Delvoux B, Gressner AM. Expression of Smads during in vitro transdifferentiation of hepatic stellate cells to myofibroblasts. Biochem Biophys Res Commun 2001; 283:554–562.
344. Arora PD, McCulloch CA. The deletion of transforming growth factor β–induced myofibroblasts depends on growth conditions and actin organization. Am J Pathol 1999; 155:2087–2099.
345. Saile B, Knittel T, Matthes N, Schott P, Ramadori G. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol 1997; 151:1265–1272.
346. Serini G, Gabbiani G. Minireview: mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 1999; 250:273–283.